MAY 29, 2014
- Galderma positioned to commercialize Restylane®, Perlane®, Emervel®, Sculptra®, Dysport® in
the U.S. and Canada - Galderma reinforces long‐term commitment to meet physician and patient needs in aesthetic and corrective dermatology worldwide
Fort Worth, Texas (May 28, 2014) – Galderma Laboratories, L.P. (“Galderma”) announced today that Nestlé S.A., Switzerland, one of Galderma’s shareholders, has entered into an agreement with Valeant Pharmaceuticals International, Inc. and related entities (“Valeant”), through which Galderma will become the distributor of several key products in aesthetic dermatology. Galderma will gain full rights to
commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.
Humberto C. Antunes, President & CEO of Galderma worldwide, based in Lausanne, Switzerland, expressed, “We are very grateful that Nestlé has continued to support Galderma through this transaction. The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness. Thanks to this agreement with Valeant,
Galderma will be able to provide this best‐in‐class portfolio of fillers and muscle relaxant for aesthetic and corrective dermatology also in the United States and Canada.”
Stuart Raetzman, CEO of Galderma Laboratories, L.P. and Galderma North America, said from Fort Worth, Texas, “This further marks the commitment of Galderma employees in the United States and Canada to aesthetic and corrective dermatology. We all work together to maintain the industry’s highest standards of clinical safety and efficacy, to bring a wide range of scientifically advanced and clinically proven medical solutions to physicians. Our portfolio of products, combined with exclusive services and medical training programs, positions Galderma as the preferred partner of dermatologists, plastic surgeons and aesthetic physicians.”
Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre‐existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these innovative and leading brands globally.
Sculptra is owned by Valeant. Through this transaction Galderma is acquiring this product and will commercialize it in the U.S. and Canada and select other markets around the world.
Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. Through this transaction, Galderma will gain the right to commercialize Dysport for aesthetic dermatology indications in the U.S. and Canada.
This transaction is also subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisors, and Debevoise and Plimpton as legal advisors to Galderma.
In February 2014, Nestlé announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oréal. The transaction between Nestlé and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.
commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.
Humberto C. Antunes, President & CEO of Galderma worldwide, based in Lausanne, Switzerland, expressed, “We are very grateful that Nestlé has continued to support Galderma through this transaction. The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness. Thanks to this agreement with Valeant,
Galderma will be able to provide this best‐in‐class portfolio of fillers and muscle relaxant for aesthetic and corrective dermatology also in the United States and Canada.”
Stuart Raetzman, CEO of Galderma Laboratories, L.P. and Galderma North America, said from Fort Worth, Texas, “This further marks the commitment of Galderma employees in the United States and Canada to aesthetic and corrective dermatology. We all work together to maintain the industry’s highest standards of clinical safety and efficacy, to bring a wide range of scientifically advanced and clinically proven medical solutions to physicians. Our portfolio of products, combined with exclusive services and medical training programs, positions Galderma as the preferred partner of dermatologists, plastic surgeons and aesthetic physicians.”
Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre‐existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these innovative and leading brands globally.
Sculptra is owned by Valeant. Through this transaction Galderma is acquiring this product and will commercialize it in the U.S. and Canada and select other markets around the world.
Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. Through this transaction, Galderma will gain the right to commercialize Dysport for aesthetic dermatology indications in the U.S. and Canada.
This transaction is also subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisors, and Debevoise and Plimpton as legal advisors to Galderma.
In February 2014, Nestlé announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oréal. The transaction between Nestlé and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.
see original article here
http://www.galderma.com/News/articleType/ArticleView/articleId/59/Galderma-to-gain-rights-to-Restylane-Perlane-Sculptra-and-Dysport-in-the-United-States-and-Canada
No comments:
Post a Comment